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Objectives. We examined cause of death in relation to age,
length of follow-up and other baseline characteristics in patients
in the 1985–1986 National Heart, Lung, and Blood Institute
Percutaneous Transluminal Coronary Angioplasty (NHLBI PTCA)
Registry.
Background. The manner in which cardiac versus noncardiac
mortality of patients with coronary revascularization varies in
relation to patient and study characteristics has not been well
documented.
Methods. Cause of death determined from a review of 5 years of
annual follow-up forms and death certificates was analyzed in
2,127 patients who had coronary angioplasty (mean age 57.6
years) without acute myocardial infarction.
Results. Within 5 years of the initial procedure, there were 205
deaths (9.6%), with 52.7% attributed to cardiac causes. Patients
with a low baseline ejection fraction, history of hypertension,
previous bypass surgery, previous myocardial infarction, inoper-
able or high surgical risk or multivessel disease had significantly
higher 5-year cardiac mortality. Patients with a history of diabe-
tes, congestive heart failure or severe concomitant noncardiac
disease had higher rates of both cardiac and noncardiac mortal-
ity. As length of follow-up increased, older patients died of
noncardiac causes more often than cardiac causes. Age >265 years
was a strong independent predictor of 5-year noncardiac mortality
(p < 0.001), but not cardiac mortality (p 5 0.08).
Conclusions. All-cause mortality rates may be high in elderly
revascularized patients, yet cardiac mortality may be less than
that expected because of a high risk of noncardiac death. Although
all-cause mortality is a more reliable end point than cause-specific
mortality, both cardiac and all-cause mortality should be consid-
ered in coronary intervention studies involving older patients and
long-term follow-up.
(J Am Coll Cardiol 1997;30:881–7)
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Over the past two decades, long-term mortality has been used
as an end point after coronary revascularization (1,2). In some
reports (3,4), cardiac and noncardiac causes of death have
been analyzed together, whereas in others they have been
separated. The relation between age, length of follow-up and
cause of mortality (cardiac vs. noncardiac) has not been well
documented. This is important because mortality from noncar-
diac causes may, theoretically, obscure interpretation of the
long-term effects of coronary revascularization, particularly in
nonrandomized studies. Indeed, the results from several lon-
gitudinal (.1 year) coronary intervention studies (Appendix,
Table A1) suggest that the cardiac/noncardiac mortality rate
ratio tends to decrease as patient age within the study cohort or
length of study follow-up, or both, increase. Accordingly, we
examined cause of death over a 5-year follow-up period in
relation to age, time since first percutaneous transluminal
coronary angioplasty (PTCA) procedure and other patient
characteristics in the 1985–1986 National Heart, Lung, and
Blood Institute (NHLBI) PTCA Registry.
Methods
Patient group. From 16 participating NHLBI PTCA Reg-
istry sites, 2,127 consecutive patients who underwent first-time
PTCA outside the setting of an acute myocardial infarction
(MI) (within the last 10 days) were included, as previously
described (2,5–7). All subjects gave written informed consent
for routine annual follow-up after the initial procedure. The
study protocol was approved by the Institutional Review Board
for Biomedical Research at the University of Pittsburgh,
Coordinating Center for the Registry. The mean age of the
cohort was 57.6 years (27% were $65 years old), 25.6% were
women, 51.5% had multivessel disease and 97.0% were
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symptomatic before or at the time of the initial procedure,
or both.
Patient follow-up and ascertainment of cause of death.
Five-year follow-up data were available on 2,064 (97%) of the
baseline cohort of 2,127 patients. Of the remaining 63 patients
with incomplete follow-up, 40 (1.9%) were lost to follow-up
and 23 (1.1%) refused follow-up. In conjunction with routine
annual contact made with participating site coordinators since
1985–1986, periodic searches of the National Death Index
were conducted to identify previously unknown deaths among
patients with incomplete follow-up data. Death certificates
were obtained for all but five patients known to have died
within 5 years of their index procedure. Cause of death was
ascertained by physician review (D.R.H.) of patient follow-up
forms and death certificates. Each patient was classified into
one of the following mutually exclusive categories: alive,
periprocedural death, death due to congestive heart failure
(CHF), sudden cardiac death, death due to MI or noncardiac
cause of death. Deaths classified as periprocedural included
patients with complications during their index procedure or as
a result of repeat revascularization either by PTCA or coronary
artery bypass graft surgery (CABG). For the five deceased
patients without death certificates, cause of death was deter-
mined by a review of patient follow-up forms and baseline
medical history (e.g., history of CHF, number of diseased
vessels). Three of these five patients were considered to have
died of cardiac causes. Parallel analyses were performed with
and without these five patients, and the results were virtually
identical.
Statistical analysis. Cardiac and noncardiac mortality over
5 years of follow-up was estimated by use of life-table analysis
(8). This included estimates within baseline subgroups. Deaths
due to noncardiac causes were censored in determining cardiac
mortality, and vice versa. Similarly, in the estimation of
individual cardiac causes of death, deaths from all other causes
were censored. To illustrate cause-specific censoring (e.g., to
determine cardiac mortality) for patients who did not die from
a cardiac cause, follow-up time was determined by the maximal
number of days from study entry to last follow-up or death of
a noncardiac cause. Although death is a one-time event,
estimating mortality rates in this manner theoretically permits
a cause-specific death after a patient is censored for another
cause-specific death (9). Because theoretic cause-specific
deaths are not mutually exclusive, the sum of mortality rates
for individual causes will always be greater or equal to the
mortality rate of the combined causes (i.e., cardiac mortality
plus noncardiac mortality greater than or equal to all-cause
mortality) (10). Cox regression analysis (11) was used to assess
the relative risk (RR) of older age ($65 years) and other
baseline factors on cardiac, noncardiac and all-cause mortality
at different follow-up intervals. A cumulative set of 25 baseline
(predilation) variables that were collected from the baseline
form (and were primarily cardiac in nature) were initially
screened by univariable analysis (at p , 0.10). The remaining
variables were subsequently assessed (at p , 0.10) using
stepwise selection. Baseline ejection fraction was excluded
from stepwise models because of substantial missing data and
because attempts to impute values for the missing data (using
other baseline variables) proved to be unreliable. Estimates of
RR were declared significant at p , 0.05.
Results
Cause-specific mortality and relation to follow-up. There
were 205 deaths (9.6%) in the cohort within 5 years of the
initial procedure, with slightly more than half of the deaths
(52.7%) being attributed to cardiac causes (Table 1). The
leading cardiac causes of death were sudden death and MI.
Twenty-two deaths (1.0%) occurred within the first 30 days of
follow-up, 17 of which were from cardiac causes (Fig. 1).
Hence, roughly 10% of the total deaths occurred within the
first 30 days. During the first 2 years after the initial procedure,
patients died increasingly more often from cardiac causes than
from noncardiac causes. In contrast, during years 3 through 5,
the divergence between cardiac and noncardiac mortality
decreased. Roughly 80% of the periprocedural deaths oc-
curred within the first year after the initial procedure (Fig. 2),
although, on average, 42% of the total cohort underwent
repeat PTCA or CABG, or both, at some time during the
5-year follow-up. Among the 18 patients who died of a
periprocedural cause, the median time to first repeat revas-
cularization was 36.5 days, and the median time to death was
Abbreviations and Acronyms
CABG 5 coronary artery bypass graft surgery
CHF 5 congestive heart failure
MI 5 myocardial infarction
NHLBI 5 National Heart, Lung, and Blood Institute
PTCA 5 percutaneous transluminal coronary angioplasty
RR 5 relative risk
Table 1. Five-Year Cause of Death in the 1985–1986 NHLBI PTCA
Registry (n 5 2,127)
Cause of Death No. of Deaths % of Cohort
Total cardiac 108 5.1
MI 29 1.4
CHF 22 1.0
Sudden cardiac 39 1.8
Periprocedural 18 0.8
Noncardiac 97 4.6
Total (cardiac and noncardiac) 205 9.6
CHF 5 congestive heart failure; MI 5 myocardial infarction; NHLBI 5
National Heart, Lung, and Blood Institute; PTCA 5 percutaneous transluminal
coronary angioplasty.
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139 days. The occurrence of CHF, MI and sudden cardiac
death increased steadily over the study period, with nearly
2% of all patients having died of sudden cardiac death by 5
years.
Subgroup cause-specific mortality. Table 2 displays the
5-year incidence of cardiac and noncardiac mortality in rela-
tion to baseline characteristics. Patients with low ejection
fraction, history of hypertension, previous CABG, previous
MI, inoperable or high surgical risk or triple-vessel disease had
significantly higher 5-year cardiac mortality. These prognostic
factors were not evident for noncardiac mortality. In contrast,
patients $65 years old or with a history of diabetes, CHF or
severe concomitant noncardiac disease had significantly higher
cardiac and noncardiac mortality.
Predictors of cardiac and all-cause mortality. During the
first year after the initial procedure, history of CHF, inopera-
ble or high surgical risk status and older patient age were
strong independent predictors of both cardiac and all-cause
mortality (Table 3). The consistency of these prognostic factors
was influenced by the preponderance of deaths that occurred
from cardiac causes (36 of 58) during the first year. In years 2
through 5, 72 (49.0%) of 147 deaths were attributed to cardiac
causes. Severe concomitant noncardiac disease at baseline and
history of hypertension emerged as significant predictors of
cardiac and all-cause mortality. In addition, variant angina and
previous CABG conferred increased risk of cardiac-only mor-
tality during this interval. Older patient age ($65 years) was
predictive of all-cause mortality during years 2 through 5, but
not cardiac-only mortality.
Cardiac and noncardiac mortality in relation to patient age
and follow-up. Consistent with the results in Table 3, a
pronounced shift from cardiac to noncardiac mortality was
evident in older patients (Fig. 3), with patients $65 years old
initially more likely to die of cardiac causes, yet by 5 years,
more likely to have died of noncardiac causes (10.1% vs.
8.2%). Table 4 further illustrates the independent effect of
patient age on mortality. Older age conferred a more than
threefold risk of both cardiac and noncardiac mortality in
the first year after the initial procedure. The excess risk
associated with older age remained evident for noncardiac
mortality in later years (years 2 through 5) of follow-up
(RR 2.92, p , 0.001), but was not evident for cardiac-only
mortality (RR 1.06, p 5 0.83). Overall, older age was a
strong independent predictor of 5-year noncardiac mortality
(RR 3.30, p , 0.001), yet was not significantly related to
cardiac mortality.
Discussion
The results of this study show that within 5 years of an initial
PTCA procedure, patients in the 1985–1986 NHLBI PTCA
Registry were about equally likely to die of noncardiac causes
of death as of cardiac causes. Patients with classic cardiac risk
factors such as previous CABG had higher rates and risk of
5-year cardiac mortality, yet some established cardiac risk
factors (history of CHF and diabetes) were also indicative of
elevated rates of noncardiac mortality. From these findings, it
is clear that patients undergoing revascularization for symp-
Figure 1. Cardiac (solid curve) and noncardiac mortality
(dashed curve).
Figure 2. Cause-specific cardiac mortality. Long-dashed
curve 5 CHF; short-dashed curve 5 MI; solid curve 5
periprocedural death; dot–dashed curve 5 sudden cardiac
death.
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Table 2. Incidence of 5-Year Cardiac and Noncardiac Deaths by Baseline Factors
Baseline Factor*
No. of
Pts
Cardiac Causes of Death 5-Year
Cardiac
Mortality
5-Year
Noncardiac
MortalityMI CHF Sudden Peri
Overall 2,127 1.4 1.1 2.0 0.9 5.3 4.8
Gender
Male 1,582 1.3 1.0 1.7 0.7 4.7 4.4
Female 545 1.7 1.4 2.4 1.5 7.0† 6.0
Age
,65 years 1,558 1.2 0.6 1.8 0.7 4.2 2.9
$65 years 569 2.2 2.5§ 2.3 1.4 8.2§ 10.1§
History of CHF
No 1,981 1.3 0.7 1.5 0.6 4.1 4.2
Yes 109 4.2† 9.0§ 10.5§ 6.7§ 27.2§ 15.7§
Severe concomitant noncardiac
disease
No 1,686 1.1 1.0 1.8 0.9 4.7 4.5
Yes 105 4.1‡ 5.2§ 3.2 3.0† 14.7§ 12.9§
LVEF
,50% 276 2.7 3.6§ 3.9‡ 1.1 10.8§ 5.6
$50% 1,193 1.1 0.6 1.3 0.8 3.8 5.0
Family history of CAD before age 55
years
No 980 1.2 1.0 2.0 0.6 4.7 4.8
Yes 902 1.3 1.5 2.0 1.1 5.8 4.2
History of cholesterol .250 mg/
100 ml
No 1,202 1.0 1.2 2.0 1.1 5.3 4.3
Yes 628 2.0 1.0 2.2 0.7 5.8 6.1
History of diabetes
No 1,824 1.3 0.9 1.4 0.7 4.3 4.3
Yes 283 2.2 2.0 5.5§ 1.8 11.1§ 8.6‡
History of hypertension
No 1,142 1.2 0.9 1.0 0.5 3.6 4.2
Yes 966 1.7 1.2 3.0‡ 1.4† 7.2§ 5.6
Previous CABG
No 1,868 1.2 0.8 1.6 0.7 4.2 4.7
Yes 259 3.0† 3.4§ 4.7‡ 2.5‡ 12.9§ 5.4
Previous MI
No 1,337 1.1 0.9 1.5 0.7 4.1 4.8
Yes 758 2.1 1.6 2.8† 0.9 7.2‡ 4.8
Inoperable or high surgical risk
No 1,647 0.9 0.7 1.5 0.8 3.9 4.8
Yes 137 5.5§ 8.3§ 6.9§ 3.0‡ 21.7§ 7.0
Unstable angina
No 1,029 1.0 1.6 1.6 1.0 5.1 4.7
Yes 1,098 1.8 0.7 2.3 0.8 5.5 4.9
Vessel disease
Single 1,031 0.9 0.4 1.2 0.3 2.8 4.3
Double 664 1.6 1.6 2.1 0.9 6.1 5.4
Triple 432 2.5 2.0† 3.6† 2.2‡ 9.9§ 5.0
Previous smoker
No 1,204 1.6 1.0 1.9 0.9 5.3 4.8
Yes 855 1.1 1.2 1.5 0.8 4.6 4.5
Current smoker
No 1,470 1.4 1.2 1.6 1.1 5.2 4.6
Yes 589 1.2 0.7 2.2 0.4 4.4 5.0
*Missing cases exist for some baseline factors. †p , 0.05. ‡p , 0.01. §p , 0.001. CABG 5 coronary artery bypass graft surgery. CAD 5 coronary artery disease;
CHF 5 congestive heart failure; LVEF 5 left ventricular ejection fraction; MI 5 myocardial infarction; Peri 5 periprocedural; Pts 5 patients.
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tomatic coronary artery disease often possess a variety of
comorbid conditions, both cardiac and noncardiac in nature,
and these conditions may yield high rates of both cardiac and
noncardiac mortality.
Competing risks associated with age and follow-up. As
suggested by previous reports of cardiac and noncardiac mor-
tality in patients who have had CABG or PTCA (Appendix),
older age and increased length of follow-up were predictive of
a shift from cardiac to noncardiac causes of death in patients in
the Registry. Because age is a risk factor for most chronic
diseases, the probability of patients of advanced age with
cardiovascular disease dying of a noncardiac cause is higher
than in that of younger patients. Moreover, as the time of study
follow-up increases, the relative influence of periprocedural
mortality on the cardiac/noncardiac mortality rate ratio dimin-
ishes. Hence, the competing risk of death from noncardiac
causes in patients undergoing coronary revascularization is
related to both age at study entry and length of study follow-
up.
Methodologic considerations. Our results have several im-
portant methodologic implications. First, in studies of patients
undergoing coronary revascularization, both all-cause mortal-
ity and cardiac-only mortality should be considered as study
outcomes if the cohort under study is relatively advanced in
age and to be followed long-term. This seems particularly
relevant to today’s interventional cardiology environment,
where patients with advanced age and advanced coronary
artery disease routinely undergo percutaneous and surgical
procedures. Cardiac mortality is an important end point for
evaluating the specific impact of coronary revascularization.
However, all-cause mortality is also necessary because of the
known unreliability of cause of death ascertainment from
death certificate data (12–15). Moreover, the cost and man-
power associated with cause of death adjudication within a
study can be substantial. Therefore, all-cause mortality should
never be replaced by cardiac-only mortality, but rather the two
end points should be complementary. In addition, nonfatal
clinical outcomes (i.e., repeat revascularization) and quality-
of-life measures (i.e., functional status) are important and
useful as outcomes in studies involving elderly patients and
long-term follow-up.
Second, when all-cause mortality is used as an end point in
coronary revascularization studies, sufficient consideration
should be given (in both the planning and analysis phases of
the study) to the expected noncardiac disease mortality to be
experienced by the cohort during the follow-up period. High
Table 3. Predictors of Cardiac and All-Cause Mortality
Factor
Univariate Analysis Multivariate Analysis
Cardiac All-Cause Cardiac All-Cause
RR 95% CI RR 95% CI RR 95% CI RR 95% CI
Risk in year 1 n 5 2,127 n 5 2,127 n 5 1,750 n 5 1,750
Age $65 yr (vs. age ,65 yr) 4.95‡ 2.51–9.78 5.33‡ 3.10–9.16 3.04† 1.37–6.74 3.62‡ 1.89–6.94
History of CHF 14.0‡ 7.22–27.2 11.0‡ 6.34–18.9 7.40‡ 3.25–16.8 5.35‡ 2.73–10.5
Multivessel disease 3.34† 1.52–7.33 2.74‡ 1.52–4.93 2.23 0.89–5.59 1.85 0.94–3.62
Inoperable or high surgical risk 10.9‡ 5.17–22.8 5.72‡ 3.11–10.5 3.87† 1.68–8.93 2.12* 1.06–4.27
Female (vs. male) 2.35* 1.22–4.54 2.56‡ 1.53–4.30 NE 1.72 0.92–3.23
Risk in years 2 to 5\ n 5 2,044 n 5 2,044 n 5 1,666 n 5 1,666
Age $65 yr (vs. age ,65 yr) 1.28 0.79–2.12 2.08‡ 1.50–2.88 NE 1.54* 1.07–2.22
History of CHF 5.65‡ 3.09–10.3 4.51‡ 2.86–7.10 3.25‡ 1.62–6.52 2.50‡ 1.48–4.22
Multivessel disease 2.55‡ 1.52–4.27 1.59† 1.14–2.22 1.89* 1.01–3.55 1.63* 1.11–2.39
Inoperable or high surgical risk 4.89‡ 2.77–8.65 2.99‡ 1.89–4.73 2.01* 1.05–3.86 1.75* 1.06–2.89
Severe concomitant disease§ 3.34‡ 1.70–6.57 3.33‡ 2.06–5.36 2.13* 1.03–4.41 2.41‡ 1.44–4.04
Previous CABG 3.21‡ 1.93–5.33 1.76† 1.16–2.67 2.46† 1.36–4.47 NE
History of diabetes 2.06* 1.18–3.59 1.97‡ 1.33–2.92 1.67 0.92–3.02 1.50 0.97–2.30
History of hypertension 1.92† 1.19–3.11 1.76‡ 1.26–2.45 2.03* 1.18–3.50 1.52* 1.06–2.20
Variant angina 2.52* 1.16–5.50 1.71 0.90–3.26 2.57* 1.16–5.71 NE
Overall risk at 5 years n 5 2,044 n 5 2,044 n 5 1,666 n 5 1,666
Age $65 yr (vs. age ,65 yr) 2.06‡ 1.40–3.01 2.70‡ 2.05–3.55 1.46 0.95–2.25 2.03‡ 1.49–2.75
History of CHF 8.19‡ 5.31–12.6 6.20‡ 4.41–8.71 4.22‡ 2.54–7.02 3.36‡ 2.26–5.00
Multivessel disease 2.78‡ 1.81–4.27 1.84‡ 1.38–2.45 1.95* 1.16–3.28 1.57* 1.11–2.21
Inoperable or high surgical risk 6.45‡ 4.15–10.0 3.69‡ 2.57–5.31 2.77‡ 1.66–4.62 1.83† 1.22–2.75
Severe concomitant disease§ 3.41‡ 1.96–5.93 3.17‡ 2.10–4.78 1.77 0.97–3.21 2.04† 1.31–3.18
Previous CABG 3.22‡ 2.13–4.86 2.16‡ 1.55–3.01 1.73* 1.04–2.87 1.41 0.95–2.09
History of diabetes 2.71‡ 1.77–4.13 2.37‡ 1.73–3.25 1.62 1.00–2.62 1.58* 1.10–2.25
History of hypertension 2.06‡ 1.39–3.06 1.67‡ 1.26–2.20 1.90† 1.21–2.99 1.39* 1.01–1.90
*p , 0.05. †p , 0.01. ‡p , 0.001. §Refers to noncardiac disease. \Follow-up time and deaths within the first year of follow-up were excluded from the analysis.
CI 5 confidence interval; NE 5 not entered into model; RR 5 relative risk; other abbreviations as in Table 2.
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noncardiac mortality may lead to inappropriate study conclu-
sions. For example, a previously suggested survival advantage
of a particular revascularization strategy in a cohort of younger
patients might appear less profound in a cohort of older-aged
patients. In short, if noncardiac mortality is high and is similar
across revascularization strategies, the relative advantage of a
particular therapy on all-cause mortality will be diluted. In
contrast, direct assessment of cardiac mortality is also obscured
by the competing risk of a noncardiac death. Cardiac mortality
rates in an elderly population may be less than expected
because of a high risk for noncardiac death.
Finally, given the shift from cardiac to noncardiac causes of
death as age and length of follow-up increase, analyses of
coronary revascularization cases may be most informative if
early periprocedural mortality is described separately from
long-term mortality and the cohort is subdivided into discrete
follow-up intervals (i.e., first year, years 2 through 5).
Study limitations. Despite a careful review of all available
documentation, cause of death ascertainment was based
largely on death certificate data and was determined by a single
physician. As previously noted, cause of death ascertainment
from death certificates may be unreliable (12–15), and misclas-
sification of cause of death could have occurred. Assuming
nondifferential cause of death misclassification, the probable
net effect would be biased toward the null. This rationale
would also apply to the 63 patients (3% of study cohort) with
incomplete follow-up in whom misclassification may have
occurred. The life-table estimates for cardiac and noncardiac
mortality in this report also assume statistical independence of
the times to cardiac and noncardiac death—an assumption that
cannot be tested.
In addition, all of the Registry patients were treated in
1985–1986, with 5-year follow-up extending into 1991. Tech-
nologic advances in the field of interventional cardiology over
the last decade, including widespread use of stents and in-
creased use of platelet glycoprotein IIb/IIIa inhibitors, may be
providing improved long-term survival after more recent cor-
onary revascularization. Therefore, it is possible that the
cardiac/noncardiac mortality rate ratio would be different in a
cohort of similar patients treated today and followed long-
term. This possibility further underscores the importance of
investigating all-cause and cause-specific mortality in coronary
intervention studies involving elderly patients and long-term
follow-up.
Conclusions. In this follow-up study of 2,127 consecutive
patients undergoing initial PTCA in the 1985–1986 NHLBI
PTCA Registry, at 5 years after the index procedure, 9.6%
had died. Cardiac causes were identified in 52.7%, with the
leading cause secondary to sudden cardiac death or MI. The
majority of cardiac deaths occurred within the initial 2 years;
after this, the majority of deaths were related to noncardiac
causes. On multivariate analysis, age $65 years was an
independent predictor of 5-year mortality but not cardiac
mortality. Although all-cause mortality is a more reliable
end point than cause-specific mortality, both cardiac and
all-cause mortality should be considered in coronary inter-
vention studies involving older patients and long-term
follow-up.
Figure 3. Cardiac (thin [age ,65 years] and thick [age .65
years] solid curves) and noncardiac mortality (dotted [age
,65 years] and dashed [age .65 years] curves) by age.
Table 4. Relative Risk of Baseline Factor Age $65 Years on Short- and Long-Term Mortality
Age $65 yr vs. age ,65 yr
Univariate Analysis
(n 5 2,127)
Multivariate Analysis
(n 5 2,090)*
Cardiac Noncardiac Cardiac Noncardiac
RR 95% CI RR 95% CI RR 95% CI RR 95% CI
Risk in year 1 4.95‡ 2.51–9.78 6.03‡ 2.46–14.8 3.04† 1.37–6.74 4.81† 1.79–13.0
Risk in years 2 to 5§ 1.28 0.78–2.12 3.18‡ 2.02–5.0 1.06 0.61–1.84 2.92‡ 1.71–5.0
Overall risk in years 1 to 5 2.06‡ 1.40–3.01 3.65‡ 2.45–5.45 1.46 0.95–2.25 3.30‡ 2.05–5.33
*Varies from 1,652 to 2,090 in multivariate models owing to missing data for some covariates. †p , 0.01. ‡p , 0.001. §Follow-up time and deaths within the first
year of follow-up were excluded from the analysis. CI 5 confidence interval; RR 5 relative risk.
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Table A1. Results of Longitudinal (.1 year) Coronary Interventional Studies*
Reference
No. of
Pts
Mean
Age
(yr)
Mean
Follow-Up
(yr)
Cardiac
Death Rate (%)†
Noncardiac
Death Rate (%)†
C/NC Rate
Ratio‡
J Am Coll Cardiol 1990;7:1569–74 130 36 3.7 5.4 0.8 6.75
Eur Heart J 1992;13:781–6 899 55 5.0 9.2 1.6 5.75
J Thorac Cardiovasc Surg 1982;84:219–23 70 55 1.9 4.3 1.4 3.07
Ann Thorac Surg 1992;53:258–62 100 51 5.0 8.0 3.0 2.67
Lancet 1989;8662:546–50 412 53 5.0 4.2 2.8 1.50
Circulation 1988;77:820–9 427 54 5.0 1.9 1.8 1.06
Lancet 1982;8309:1173–80 450 50 5.0 2.0 3.3 0.61
Am J Cardiol 1994;73:1041–6 159 65 3.3 7.5 1.9 3.95
Br Heart J 1995;74:310–7 163 73 2.9 7.4 2.5 2.96
J Am Coll Cardiol 1990;16:57–65 213 53 9.0 6.6 2.3 2.87
Thorac Cardiovasc Surg 1989;37:80–3 123 36 9.1 13.0 6.5 2.00
Ann Thorac Surg 1992;53:258–62 100 51 15.0 32.0 17.0 1.88
100 51 20.0 39.0 21.0 1.86
100 51 10.0 21.0 12.0 1.75
Am Heart J 1989;117:71–81 7,197 56 6.0 6.2 3.7 1.68
J Am Coll Cardiol 1993;22:353–60 133 50 10.0 6.0 3.8 1.58
Ann Thorac Surg 1983;36:540–7 76 54 9.0 3.9 2.6 1.50
Am Heart J 1992;124:1169–74 103 59 4.1 5.8 3.9 1.49
N Engl J Med 1987;316:1127–32 133 50 6.0 3.8 3.0 1.27
J Cardiovasc Surg 1992;33:554–9 7,322 66 13.0 12.1 9.5 1.27
J Cardiovasc Surg 1986;27:650–6 126 50 10.0 20.6 16.7 1.23
Am Heart J 1992;124:1159–69 798 53 8.0 4.5 3.8 1.18
Ann Thorac Surg 1982;34:559–63 380 60 5.2 5.8 5.0 1.16
J Thorac Cardiovasc Surg 1982;84:219–23 66 72 2.0 3.0 3.0 1.00
Am Thorac Surg 1989;47:595–9 266 54 11.9 11.7 12.0 0.98
JAMA 1986;256:2967–71 1,434 54 8.8 16.4 24.7 0.66
J Thorac Cardiovasc Surg 1991;102:532–8 77 83 1.8 2.6 15.6 0.17
*Studies with enrollment restricted to extreme high risk patients (Pts) (e.g., patients with low ejection fraction, previous bypass surgery or acute myocardial
infarction) were not included. †Within-subgroup mortality rates were used in some studies (e.g., young vs. old patients, patients with bypass surgery but not those
medically treated); some studies contributed more than one data point when cardiac and noncardiac mortality were reported at different follow-up intervals (e.g., 5
years, 10 years); Kaplan-Meier estimates were usually used when available for cardiac and noncardiac deaths; otherwise, crude event rates were used on the basis of
mean or median length of follow-up; in some instances, the numerators and denominators used in event rate calculations exclude in-hospital mortality. ‡Mean (6SD)
cardiac (C)/noncardiac (NC) death rate ratio: 3.06 6 2.36 for age #50 years and follow-up #5 years; 1.62 6 0.85 for age .50 years or follow-up .5 years.
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